RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Beijing Sun-Novo Pharmaceutical Research Co Stock

Beijing Sun-Novo Pharmaceutical Research Co Equity 2025

Beijing Sun-Novo Pharmaceutical Research Co Equity

1.04 B CNY

Ticker

688621.SS

ISIN

CNE100005139

In 2025, Beijing Sun-Novo Pharmaceutical Research Co's equity was 1.04 B CNY, a 15.98% increase from the 896.7 M CNY equity in the previous year.

Beijing Sun-Novo Pharmaceutical Research Co Aktienanalyse

What does Beijing Sun-Novo Pharmaceutical Research Co do?

Beijing Sun-Novo Pharmaceutical Research Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Beijing Sun-Novo Pharmaceutical Research Co's Equity

Beijing Sun-Novo Pharmaceutical Research Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Beijing Sun-Novo Pharmaceutical Research Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Beijing Sun-Novo Pharmaceutical Research Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Beijing Sun-Novo Pharmaceutical Research Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Beijing Sun-Novo Pharmaceutical Research Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Beijing Sun-Novo Pharmaceutical Research Co stock

What is the equity of Beijing Sun-Novo Pharmaceutical Research Co this year?

Beijing Sun-Novo Pharmaceutical Research Co has equity of 1.04 B CNY this year.

What was the equity of Beijing Sun-Novo Pharmaceutical Research Co compared to the previous year?

The equity of Beijing Sun-Novo Pharmaceutical Research Co has increased/decreased by 15.98% increased compared to the previous year.

What impact does a high equity have on investors of Beijing Sun-Novo Pharmaceutical Research Co?

A high equity is advantageous for investors of Beijing Sun-Novo Pharmaceutical Research Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Beijing Sun-Novo Pharmaceutical Research Co?

A low equity can be a risk for investors of Beijing Sun-Novo Pharmaceutical Research Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Beijing Sun-Novo Pharmaceutical Research Co affect the company?

An increase in equity of Beijing Sun-Novo Pharmaceutical Research Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Beijing Sun-Novo Pharmaceutical Research Co affect the company?

A reduction in equity of Beijing Sun-Novo Pharmaceutical Research Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Beijing Sun-Novo Pharmaceutical Research Co?

Some factors that can affect the equity of Beijing Sun-Novo Pharmaceutical Research Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Beijing Sun-Novo Pharmaceutical Research Co so important for investors?

The equity of Beijing Sun-Novo Pharmaceutical Research Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Beijing Sun-Novo Pharmaceutical Research Co take to change the equity?

To change equity, Beijing Sun-Novo Pharmaceutical Research Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Beijing Sun-Novo Pharmaceutical Research Co pay?

Over the past 12 months, Beijing Sun-Novo Pharmaceutical Research Co paid a dividend of 0.43 CNY . This corresponds to a dividend yield of about 1.17 %. For the coming 12 months, Beijing Sun-Novo Pharmaceutical Research Co is expected to pay a dividend of 0.49 CNY.

What is the dividend yield of Beijing Sun-Novo Pharmaceutical Research Co?

The current dividend yield of Beijing Sun-Novo Pharmaceutical Research Co is 1.17 %.

When does Beijing Sun-Novo Pharmaceutical Research Co pay dividends?

Beijing Sun-Novo Pharmaceutical Research Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Beijing Sun-Novo Pharmaceutical Research Co?

Beijing Sun-Novo Pharmaceutical Research Co paid dividends every year for the past 5 years.

What is the dividend of Beijing Sun-Novo Pharmaceutical Research Co?

For the upcoming 12 months, dividends amounting to 0.49 CNY are expected. This corresponds to a dividend yield of 1.34 %.

In which sector is Beijing Sun-Novo Pharmaceutical Research Co located?

Beijing Sun-Novo Pharmaceutical Research Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Beijing Sun-Novo Pharmaceutical Research Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Beijing Sun-Novo Pharmaceutical Research Co from 7/9/2024 amounting to 0.165 CNY, you needed to have the stock in your portfolio before the ex-date on 7/9/2024.

When did Beijing Sun-Novo Pharmaceutical Research Co pay the last dividend?

The last dividend was paid out on 7/9/2024.

What was the dividend of Beijing Sun-Novo Pharmaceutical Research Co in the year 2024?

In the year 2024, Beijing Sun-Novo Pharmaceutical Research Co distributed 0.429 CNY as dividends.

In which currency does Beijing Sun-Novo Pharmaceutical Research Co pay out the dividend?

The dividends of Beijing Sun-Novo Pharmaceutical Research Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Beijing Sun-Novo Pharmaceutical Research Co

Our stock analysis for Beijing Sun-Novo Pharmaceutical Research Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beijing Sun-Novo Pharmaceutical Research Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.